Patricia Martínez-Moya

Patricia Martínez-Moya

Auto-generated profile, based on publicly available information

Patricia Martínez-Moya

Department of Biochemistry and Molecular Biology II, CIBERehd, School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Granada, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Analytical Biochemistry
Verified
Journal Article
Closed access
IRIsabel Romero-Calvo
Isabel Romero-Calvo
BOBorja Ocón
Borja Ocón
PMPatricia Martínez-Moya
Patricia Martínez-Moya
MSMaría Dolores Suárez
María Dolores Suárez
AZAntonio Zarzuelo
Antonio Zarzuelo
Fermin Sánchez de MedinaFermin Sánchez de Medina
Fermin Sánchez de Medina

1 February 2013 in International Immunopharmacology
Verified
Journal Article
Closed access
PMPatricia Martínez-Moya
Patricia Martínez-Moya
IRIsabel Romero-Calvo
Isabel Romero-Calvo
PRPilar Requena
Pilar Requena
Cristina Hernández ChirlaqueCristina Hernández Chirlaque
Cristina Hernández Chirlaque
CACarlos José Aranda
Carlos José Aranda
Fermin Sánchez de MedinaFermin Sánchez de Medina
Fermin Sánchez de Medina

1 February 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
RLRocío López-Posadas
Rocío López-Posadas
RGRaquel González
Raquel González
IBIsabel Ballester
Isabel Ballester
PMPatricia Martínez-Moya
Patricia Martínez-Moya
IRIsabel Romero-Calvo
Isabel Romero-Calvo
Fermin Sánchez de MedinaFermin Sánchez de Medina
Fermin Sánchez de Medina
Background. Intestinal inflammation produces an induction of alkaline phosphatase (AP) activity that is attributable in part to augmented expression, ac

1 August 2012 in Pharmacological Research
Verified
Journal Article
Closed access
PMP. Martínez-Moya
P. Martínez-Moya
MOM. Ortega-González
M. Ortega-González
RGR. González
R. González
AAA. Anzola
A. Anzola
BOB. Ocón
B. Ocón
Fermin Sánchez de MedinaFermin Sánchez de Medina
Fermin Sánchez de Medina

26 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AAAndrea Anzola
Andrea Anzola
RGRaquel González
Raquel González
RGReyes Gámez-Belmonte
Reyes Gámez-Belmonte
BOBorja Ocón
Borja Ocón
CACarlos José Aranda
Carlos José Aranda
OMOlga Martinez-Augustin
Olga Martinez-Augustin
Regulation of miR-146a abundance and its role in intestinal inflammation and particularly in intestinal epithelial cells (IECs) has been poorly studied. Here we study the relationship between bacterial antigens and inflammatory stimuli, and miR-146a expression using IEC lines and models of colitis (trinitrobenzenesulfonic acid (TNBS), dextran sulfate sodium (DSS) and the CD4 + CD62L + T cell transfer model). Specific bacterial antigens and cytokines (LPS, flagelin and IL-1β/TNF) stimulate miR-146a expression, while peptidoglycan, muramyldipeptide and CpG DNA have no effect. Overexpression of miR-146a by LPS depends on the activation of the TLR4/MyD88/NF-kB and Akt pathways. Accordingly, the induction of miR-146a is lower in TLR4, but not in TLR2 knock out mice in both basal and colitic conditions. miR-146a overexpression in IECs induces immune tolerance, inhibiting cytokine production (MCP-1 and GROα/IL-8) in response to LPS (IEC18) or IL-1β (Caco-2). Intestinal inflammation induced by chemical damage to the epithelium (DSS and TNBS models) induces miR-146a, but no effect is observed in the lymphocyte transfer model. Finally, we found that miR-146a expression is upregulated in purified IECs from villi vs. crypts. Our results indicate that miR-146a is a key molecule in the interaction among IECs, inflammatory stimuli and the microbiota.

30 December 2016 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
Cristina Hernández ChirlaqueCristina Hernández Chirlaque
Cristina Hernández Chirlaque
RGReyes Gámez-Belmonte
Reyes Gámez-Belmonte
BOBorja Ocón
Borja Ocón
PMPatricia Martínez-Moya
Patricia Martínez-Moya
SWStefan Wirtz
Stefan Wirtz
OMOlga Martinez-Augustin
Olga Martinez-Augustin
Background and Aims: Two alkaline phosphatase isoforms, intestinal [IAP] and tissue non-specific alkaline phosphatase [TNAP], are coexpressed in mouse colon, with the latter predominating in colitis. We aimed to examine the role of TNAP in T lymphocytes, using heterozygous TNAP+/- mice [as TNAP-/- mice are non-viable]. Methods: In vitro primary cultures and in vivo T cell models using TNAP+/- mice were used. Results: Stimulated splenocytes [lipopolysaccharide and concanavalin A] and T lymphocytes [concanavalin A and a-CD3/a-CD28] showed a decreased cytokine production and expression when compared with wild-type [WT] cells. Decreased T cell activation was reproduced by the TNAP inhibitors levamisole, theophylline, and phenylalanine in WT cells. Intraperitoneal administration of anti-CD3 in vivo resulted in reduced plasma cytokine levels, and decreased activation of splenocytes and T cells ex vivo in TNAP+/- mice. We further tested the hypothesis that TNAP expressed in T lymphocytes is involved in T cell activation and inflammation, using the lymphocyte transfer model of colitis. Rag1-/- mice were transferred with T naïve cells [CD4+ CD62L+] from TNAP+/- or WT mice and developed colitis, which was attenuated in the group receiving TNAP+/- cells. Compared with WT, T cells from TNAP+/- mice showed a decreased capacity for proliferation, with no change in differentiation. Conclusions: Our results offer clear evidence that TNAP modulates T lymphocyte function and specifically T cell-dependent colitis. This was associated with distinct changes in the type of TNAP expressed, probably because of changes in glycosylation.
1